Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00431756 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus

Study acronym: BE
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion pushed from Aug 31, 2026 to Aug 31, 2027v37
  2. Completion date: Jun 1, 2026 to Aug 31, 2026v36
  3. Completion date: Dec 1, 2025 to Jun 1, 2026v35
  4. Completion date: May 1, 2025 to Dec 1, 2025v34
  5. Completion date: May 1, 2024 to May 1, 2025 Collaborators: 1 to 2v33 Show 1 more changeShow less
    • Collaborators: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

Show 31 earlier versionsHide 31 earlier versions
  1. Re-verified, no change to tracked fieldsv32
  2. Start date: Jan 2002 to May 1, 2002 Primary completion date changed from estimate of Jun 2023 to May 1, 2023 · Completion date: Jun 2023 to May 1, 2024v31 Show 2 more changesShow less
    • Primary completion date changed from estimate of Jun 2023 to May 1, 2023
    • Completion date: Jun 2023 to May 1, 2024
  3. Re-verified, no change to tracked fieldsv30
  4. Primary and study completion dates: Jun 2022 to Jun 2023v29
  5. Study sites: 2 to 1v28
  6. Primary and study completion dates: Jun 2020 to Jun 2022 Trial status: Enrolling by Invitation to Active, Not Recruiting · Enrollment target: 540 to 600 · Study title expanded, about 2 wordsv27 Show 3 more changesShow less
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Enrollment target: 540 to 600
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  7. Re-verified, no change to tracked fieldsv26
  8. Trial status: Recruiting to Enrolling by Invitation Site details revised at 2 of 2 sitesv25 Show 1 more changeShow less
    • Site details revised at 2 of 2 sites
  9. Re-verified, no change to tracked fieldsv24
  10. Study description expanded, about 3 wordsv23 See this version in full on ClinicalTrials.gov ↗
  11. Primary and study completion dates: Jun 2017 to Jun 2020v22
  12. 4 versions Re-verified since Jul 16, 2015, no change to tracked fieldsv18-v21
  13. Primary and study completion dates: Jun 2015 to Jun 2017 Eligibility criteria shortened, about 14 wordsv17 Show 1 more changeShow less
    • Eligibility criteria shortened, about 14 words

    See this version in full on ClinicalTrials.gov ↗

  14. 4 versions Re-verified since Jul 25, 2013, no change to tracked fieldsv13-v16
  15. Primary completion date: Jun 2015 Site contacts updated at 1 of 2 sitesv12 Show 1 more changeShow less
    • Site contacts updated at 1 of 2 sites
  16. Completion date: Jun 2013 to Jun 2015v11
  17. Study sites: 1 to 2 Completion date: Jan 2012 to Jun 2013v10 Show 1 more changeShow less
    • Completion date: Jan 2012 to Jun 2013
  18. Re-verified, no change to tracked fieldsv9
  19. Site contact updatedv8
  20. 2 versions Re-verified since May 13, 2010, no change to tracked fieldsv6-v7
  21. Completion date: Jan 2011 to Jan 2012 Site contact updatedv5 Show 1 more changeShow less
    • Site contact updated
  22. 2 versions Re-verified since Jan 29, 2009, no change to tracked fieldsv3-v4
  23. Eligibility criteria shortened, about 1 wordv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine if there are any early changes in DNA markers of blood and esophageal tissue in people with gastric reflux, Barrett's esophagus or esophageal cancer that can warn of a progression to esophageal cancer.
Trial Details
NCT Number NCT00431756
Lead Sponsor Johns Hopkins University
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cancer Institute (NCI)
Conditions Barrett Esophagus, Esophageal Neoplasm, Gastroesophageal Reflux
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov